324 related articles for article (PubMed ID: 30824386)
1. Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway.
van Montfort T; van der Sluis R; Darcis G; Beaty D; Groen K; Pasternak AO; Pollakis G; Vink M; Westerhout EM; Hamdi M; Bakker M; van der Putten B; Jurriaans S; Prins JH; Jeeninga R; Thomas AAM; Speijer D; Berkhout B
EBioMedicine; 2019 Apr; 42():97-108. PubMed ID: 30824386
[TBL] [Abstract][Full Text] [Related]
2. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
4. Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal of latently HIV-1 infected T cells.
Carlin E; Greer B; Lowman K; Duverger A; Wagner F; Moylan D; Dalecki A; Samuel S; Perez M; Sabbaj S; Kutsch O
PLoS Pathog; 2021 Jan; 17(1):e1008748. PubMed ID: 33465149
[TBL] [Abstract][Full Text] [Related]
5. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
[TBL] [Abstract][Full Text] [Related]
6. Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection.
Palmer CS; Duette GA; Wagner MCE; Henstridge DC; Saleh S; Pereira C; Zhou J; Simar D; Lewin SR; Ostrowski M; McCune JM; Crowe SM
FEBS Lett; 2017 Oct; 591(20):3319-3332. PubMed ID: 28892135
[TBL] [Abstract][Full Text] [Related]
7. HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.
Saleh S; Lu HK; Evans V; Harisson D; Zhou J; Jaworowski A; Sallmann G; Cheong KY; Mota TM; Tennakoon S; Angelovich TA; Anderson J; Harman A; Cunningham A; Gray L; Churchill M; Mak J; Drummer H; Vatakis DN; Lewin SR; Cameron PU
Retrovirology; 2016 Jul; 13(1):49. PubMed ID: 27459960
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Vesicle Activation of Latent HIV-1 Is Driven by EV-Associated c-Src and Cellular SRC-1 via the PI3K/AKT/mTOR Pathway.
Barclay RA; Mensah GA; Cowen M; DeMarino C; Kim Y; Pinto DO; Erickson J; Kashanchi F
Viruses; 2020 Jun; 12(6):. PubMed ID: 32575590
[TBL] [Abstract][Full Text] [Related]
9. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
Front Immunol; 2021; 12():720697. PubMed ID: 34531866
[TBL] [Abstract][Full Text] [Related]
10. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
Rochat MA; Schlaepfer E; Speck RF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
[TBL] [Abstract][Full Text] [Related]
11. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1.
Doyon G; Sobolewski MD; Huber K; McMahon D; Mellors JW; Sluis-Cremer N
PLoS One; 2014; 9(1):e84964. PubMed ID: 24489654
[TBL] [Abstract][Full Text] [Related]
13. Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4
Kumar NA; van der Sluis RM; Mota T; Pascoe R; Evans VA; Lewin SR; Cameron PU
J Immunol; 2018 Sep; 201(5):1468-1477. PubMed ID: 30030324
[TBL] [Abstract][Full Text] [Related]
14. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
15. DC-based immunotherapy as strategy to purge the HIV reservoir?
Søgaard OS
EBioMedicine; 2019 May; 43():16-17. PubMed ID: 30981650
[No Abstract] [Full Text] [Related]
16. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
17. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4
Kulpa DA; Talla A; Brehm JH; Ribeiro SP; Yuan S; Bebin-Blackwell AG; Miller M; Barnard R; Deeks SG; Hazuda D; Chomont N; Sékaly RP
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578289
[TBL] [Abstract][Full Text] [Related]
18. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
19. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.
Lassen KG; Hebbeler AM; Bhattacharyya D; Lobritz MA; Greene WC
PLoS One; 2012; 7(1):e30176. PubMed ID: 22291913
[TBL] [Abstract][Full Text] [Related]
20. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection.
Mann JFS; Pankrac J; Klein K; McKay PF; King DFL; Gibson R; Wijewardhana CN; Pawa R; Meyerowitz J; Gao Y; Canaday DH; Avino M; Poon AFY; Foster C; Fidler S; Shattock RJ; Arts EJ
EBioMedicine; 2020 Sep; 59():102853. PubMed ID: 32654992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
